Back to Search
Start Over
Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009)
Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009)
- Source :
- Journal of Clinical Oncology. 36:1040-1040
- Publication Year :
- 2018
- Publisher :
- American Society of Clinical Oncology (ASCO), 2018.
-
Abstract
- 1040Background: The majority of women with ER+ MBC develop resistance to ET. ET plus a CDK4/6 inhibitor (CDKi 4/6) demonstrate improved progression-free survival (PFS) in first/later line MBC. Prec...
- Subjects :
- 0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
business.industry
Endocrine therapy
Estrogen receptor
Palbociclib
medicine.disease
Metastatic breast cancer
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
medicine
GEDATOLISIB
business
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........e3797c91bd0848baa41ab2c8a3664369
- Full Text :
- https://doi.org/10.1200/jco.2018.36.15_suppl.1040